CAMPATH Pages on BioPortfolio:

Biotechnology News CAMPATH Search
Genzymes Campath Meets Primary Endpoint in Phase 3 Combination Therapy Trial for ... Genzymeis reporting that Campath plus Fludara prolongs progression-free ...
http://www.bioportfolio.co.uk/CAMPATH-news.htm...

Campath Improves Survival of Refractory CLL Patients
15 May 2002 ... Campath demonstrated encouraging data in terms of overall objective ... Campath is indicated for use for the treatment of B-CLL in patients ...
http://www.bioportfolio.com/news/btech_051502_2.htm...

Biotechnology News LEUKINE Search
Genzyme's Campath Meets Primary Endpoint In Phase 3 Combination Therapy Trial ... oday that its randomized Phase 3 clinical trial investigating Campath(R) ...
http://www.bioportfolio.co.uk/LEUKINE-news.htm...

BioPortfolio - Campath
Based in San Antonio, Texas, ILEX has a marketed product, Campath®, a treatment for patients with refractory chronic lymphocytic leukemia. ...
http://www.bioportfolio.com/indepth/Campath.html...

BioPortfolio.com - BioWeb Thrombocytopenia Search
Overview VELCADE ® Campath ® Research and Development Clinical Trials Resources for Patients MECHANISM PHASE 3 TRIAL DESIGN PHASE 3 TRIAL RESULTS ONLY 1 ...
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=s...

BioPortfolio - Bayer HealthCare Pharmaceuticals Inc. - Bayer ...
Read Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the ... Campath is indicated in the United States as a single agent for the ...
http://www.bioportfolio.com/news/Bayer_Announces_Upcoming_Pr...

BioPortfolio.com - BioWeb Pancytopenia Search
Single doses of Campath greater than 30 mg or cumulative doses greater than 90 mg per week should not be administered because these doses are associated ...
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=s...

BTG plc: Final Phase II Results of CampathR Multiple Sclerosis ...
23 Oct 2008 ... Results show a significant and sustained reduction in disability and risk of relapse for MS patients on Campath® versus those on Rebif® ...
http://www.bioportfolio.com/biotech_news/BTG_11.htm...

Biotechnology News Anemia Refractory Search
Genzymes Campath Meets Primary Endpoint in Phase 3 Combination Therapy Trial for Chronic Lymphocytic Leukemia rovement in Progression Free Survival Seen in ...
http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=s...

BioPortfolio - Leukemia Lymphocytic Chronic - InDepth
Genzymes Campath Meets Primary Endpoint in Phase 3 Combination Therapy Trial ... BTG PLC : Campath Meets Primary Endpoin. Investegate: Sep 24 2009 1:13PM ...
http://www.bioportfolio.com/indepth/Leukemia_Lymphocytic_Chr...

Results from other life science and pharmaceutical sites:

Alemtuzumab - Wikipedia, the free encyclopedia
1 Sep 2009 ... Alemtuzumab (marketed as Campath, MabCampath or Campath-1H) is a monoclonal ... The origins of alemtuzumab date back to Campath-1 which was ...
http://en.wikipedia.org/wiki/Alemtuzumab...

Campath-1G causes rapid depletion of circulating host dendritic ...
1 Apr 2002 ... Because CD52 has been reported to be expressed on DCs, we reasoned that pretransplant Campath-1G might have a direct effect on circulating ...
http://www.ncbi.nlm.nih.gov/pubmed/11895797...

Alemtuzumab (marketed as Campath) Information
9 Sep 2009 ... This is a summary of the most important information about Campath. For more information, talk to your healthcare professional. ...
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInfo...

Mooren's ulcer resolved with campath-1H
Campath-1H is a humanised lymphocytotoxic monoclonal antibody (mAb) that targets the CD52 antigen on T lymphocytes. Successful mAb therapy using campath-1H ...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1771776/...

CAMPATH: from concept to clinic
CAMPATH-1H (alemtuzumab) was generated in an attempt to replace anti-lymphocyte globulins in the transplant arena. Its efficacy in killing lymphocytes has ...
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=15...

Population pharmacokinetics–pharmacodynamics of alemtuzumab ...
Alemtuzumab (Campath®) is a 150-kDa humanized IgG1 monoclonal antibody (MAb) ...... Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed
...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2000651/...

Information for Healthcare Professionals - Alemtuzumab (marketed ...
9 Sep 2009 ... Campath is not approved for the treatment of MS. Campath is approved for treating B-cell chronic lymphocytic leukemia (CLL) in patients who ...
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInfo...

The effects of Campath 1H upon graft-versus-host disease ...
We performed a trial using Campath 1 H pre- and post-HSCT in an attempt to decrease the incidence of GVHD without increasing the risk of infection or ...
http://www.ncbi.nlm.nih.gov/pubmed/17448918...

Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol ...
CAMPATH-1 antibodies recognize a unique molecule on human lymphocytes and are unusually efficient at causing cell lysis with homologous complement. ...
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=11...

Pharmacokinetics of CAMPATH-1H: assay development and validation.
CAMPATH-1H is a humanised monoclonal antibody against the CD52 antigen which is being developed for treatment of chronic lymphocytic leukaemia (CLL), ...
http://www.ncbi.nlm.nih.gov/pubmed/11792397...

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.